ADC Development for Osteosarcoma

Osteosarcoma represents the most frequent malignant primary bone tumor, which mainly occurs in children and adolescents and causing high mortality. To date, despite significant advancements in the diagnosis and treatment of the cancer, long-term survival in both localized and metastatic osteosarcoma is still stagnated. Thus, conventional therapy is not fully adequate for osteosarcoma treatment and novel therapeutic approaches are required to improve outcomes.

Antibody-drug conjugates (ADCs) as a targeted immunotherapy display significant advantages in cancer treatment, which also have shown great potential for the osteosarcoma treatment currently. Creative Biolabs is committed to all kinds of bio-conjugation for many years, and we have integrated technology platforms for specific ADCs development. As your value-added partner in biopharmaceutical drug development, we offers a complete range of ADCs construction services against osteosarcoma.

Introduction of Osteosarcoma

Osteosarcoma is the most common primary malignant bone tumor arising from the metaphysis of long bones. Osteosarcoma mainly occurs in teenagers and young adults, but it can also occur in younger children and older adults. Usually, symptoms of osteosarcoma include swelling near a bone, bone or joint pain and unexplained bone injury or bone break. To date, the precise cause of the cancer is not clear. Some risk factors may contribute to the disease such as the previous treatment with radiation therapy, certain inherited or genetic conditions and so on. Currently, major therapy strategies for osteosarcoma include surgery to remove the cancer cells, limb-sparing surgery to remove the tumor and tissue, amputation, rotationplasty, chemotherapy and radiation therapy.

Osteogenesis and osteosarcomagenesis. Fig.1 Osteogenesis and osteosarcomagenesis. (Lin, 2017)

Current Therapeutic Strategies for Osteosarcoma

Treatment for the osteosarcoma is generally based on the tumor entity, tumor stage, age, gender, general condition, quality of life, life expectancy, etc. Some conventional therapeutic approaches remain the main options including the surgery, chemotherapy, and palliative radiotherapy. However, some innovative therapy methods are displaying unique advantages and promise.

  • Currently, surgery is an indispensable part in osteosarcoma treatment together with chemotherapy. The purpose of surgery is to remove the complete tumor to avoid local recurrence and improve overall survival. Surgery methods mainly include amputation, limb-salvage with endoprosthetic or biological reconstruction, rotationplasty, etc.
  • Chemotherapy is still the most common therapy for osteosarcoma. If alone chemotherapy or surgery is not effective enough for treatment, a combination of them is usually used. Neoadjuvant and adjuvant chemotherapy represent the current standard regimens. Neoadjuvant chemotherapy can enhance tumor necrosis, facilitate surgical resection and eradicate micrometastases.
  • Radiotherapy is another approach in the osteosarcoma treatment. However, the use of the radiotherapy is not applied as a first-choice only in the treatment of primary osteosarcoma, because osteosarcoma is a relatively radio-resistant tumor. Thus, radiotherapy is generally used in patients with unresectable or inaccessible osteosarcoma.
  • Novel therapy strategies such as the targeted ADCs have also been introduced and applied in the osteosarcoma treatment. Glembatumumab vedotin (also known as CDX‑011) is an ADC targeting the glycoprotein non-metastatic melanoma protein B (GPNMB), which is investigated in pivotal phase II for the osteosarcoma. Clinical trials demonstrated that this ADC has effective antitumor activity.

Structures of glembatumumab vedotin (CDX‑011) Fig.2 Structures of glembatumumab vedotin (CDX‑011).

What Can We Do for You?

Creative Biolabs has extensive experience in ADCs development with expertise in antibody generation, linker-payload production and bioconjugate design and generation. We now provide a full range of ADCs preparation services for osteosarcoma treatment with developed and mature conjugation protocols. Creative Biolabs’ custom conjugation services allow the generation of high quality conjugates optimized to meet your specifications, and we promise to provide stable, reproducible conjugates efficiently within a minimal timescale.

Target of ADC development for prostate cancer:

If you are interested in our services, please feel free to contact us for more detailed information.

Reference

  1. Lin, Y. H.; et al. Osteosarcoma: molecular pathogenesis and ipsc modeling. Trends in Molecular Medicine. 2017, 23(8).

For lab research use only, not for any in vivo human use.



Online Inquiry
Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.


Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.


Contact us
USA
 45-1 Ramsey Road, Shirley, NY 11967, USA
 Tel: 1-631-357-2254
 Fax: 1-631-207-8356
 Email:
Europe
Heidenkampsweg 58, 20097 Hamburg, Germany
 Tel: 44-207-097-1828
 Email:

Inquiry

Top